1-11 of 11
Binoj Nair
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Clinical Trials & Observations
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (13): 1374–1386.
https://doi.org/10.1182/blood.2024024510
Published: 2024
Includes: Supplemental data
Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 3269.
https://doi.org/10.1182/blood-2023-181090
Published: 2023
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M.Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Marańda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah
Journal: Blood
Blood (2022) 140 (Supplement 1): 557–560.
https://doi.org/10.1182/blood-2022-159123
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael L. Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech-Marańda, Joanna M. Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo B. Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9368–9372.
https://doi.org/10.1182/blood-2022-159425
Published: 2022
Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Yoon Cheah, Jonathon B. Cohen, Lindsey E. Roeker, Manish R. Patel, Bita Fakhri, Minal A. Barve, Constantine S. Tam, David John Lewis, James N. Gerson, Alvaro J. Alencar, Chaitra S. Ujjani, Ian W. Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna M Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald Tsai, Matthew S. Davids, Jennifer R. Brown, Wojciech Jurczak
Journal: Blood
Blood (2021) 138 (Supplement 1): 391.
https://doi.org/10.1182/blood-2021-147599
Published: 2021
Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Michael Wang, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine Lewis, Timothy S. Fenske, Catherine C. Coombs, Ian W. Flinn, David John Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Jonathon B. Cohen, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Marańda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Minna Balbas, Donald Tsai, Anthony R. Mato, Chan Yoon Cheah
Journal: Blood
Blood (2021) 138 (Supplement 1): 381.
https://doi.org/10.1182/blood-2021-149138
Published: 2021
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Michael Wang, MD, Nirav N. Shah, MD, Alvaro J. Alencar, MD, James N. Gerson, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Wojciech Jurczak, MD PhD, Xuan Ni Tan, MD, Katharine L Lewis, MBBS, Timothy S. Fenske, MD, Catherine C. Coombs, MD, Ian W. Flinn, MD PhD, David John Lewis, MD, Steven Le Gouill, MD PhD, M. Lia Palomba, MD, Jennifer A. Woyach, MD, John M. Pagel, MDPhD, Nicole Lamanna, MD, Jonathon B. Cohen, MDMS, Minal Barve, MD, Paolo Ghia, MD PhD, Toby A. Eyre, Ming Yin, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Anthony Mato, MD, Chan Yoon Cheah, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
https://doi.org/10.1182/blood-2020-134314
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, MD, John M. Pagel, MDPhD, Catherine C. Coombs, MD, Nirav N. Shah, MD, Nicole Lamanna, MD, Ewa Lech-Marańda, MD PhD, Toby A. Eyre, Jennifer A. Woyach, MD, William G. Wierda, MD PhD, Chan Yoon Cheah, MBBS, Lindsey E Roeker, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Minal Barve, MD, Constantine S. Tam, MBBS, David John Lewis, MD, James N. Gerson, MD, Alvaro J. Alencar, MD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Paolo Ghia, MD PhD, Stephen J. Schuster, MD, Jessica Chen, MS, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Matthew S. Davids, MD, Jennifer R Brown, MD PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-134970
Published: 2020